Mesothelioma 
Welcome,         Profile    Billing    Logout  

278 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mesothelioma
2015-004433-26: Zoledronic acid in the management of Mesothelioma - a feasibility trial

Ongoing
4
70
Europe
Zoledronic acid, Concentrate for solution for injection, Zometa 4 mg/5 ml concentrate for solution for infusion
North Bristol NHS Trust, NIHR - RfPB funding
Malignant pleural mesothelioma, Cancer of the lung lining, usually as a consequence of previous asbestos exposure., Diseases [C] - Cancer [C04]
 
 
2018-001291-38: Improvement of treatment with pemetrexed in patients with lung cancer and asbestos cancer Verbetering van behandeling met pemetrexed bij patiënten met longkanker en asbestkanker.

Ongoing
4
117
Europe
ALIMTA, Powder for infusion, ALIMTA
Radboud University Medical Center, Radboud University Medical Center
non-small cell lung cancer, mesothelioma, lung cancer, asbestos cancer, Diseases [C] - Cancer [C04]
 
 
VATS, NCT05077111: A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia

Active, not recruiting
4
40
RoW
Thoracic Epidural Anesthesia, General Anesthesia with One Lung Ventilation
Mohamed Reda Ashour
Pleural Effusion, Malignant, Pleural Mesothelioma, Pleural Empyema, Pulmonary Diseases or Conditions, Pleural Neoplasms, Pulmonary Atelectasis, Pleural Diseases, Pericardial Effusion, Mediastinal Lymphadenopathy, Pneumothorax and Air Leak, Hemothorax, Pyopneumothorax
09/21
10/21
FLEX, NCT06010277: Folinic Acid for Prevention of Pemetrexed-induced Toxicity

Recruiting
4
50
Europe
Folinic acid
Amphia Hospital, Albert Schweitzer Hospital
NSCLC, Mesothelioma, Thymoma
01/24
01/24
ACTRN12620001199909: DREAM3R: A phase 3 trial of durvalumab with chemotherapy as first line treatment in mesothelioma

Recruiting
3
480
 
University of Sydney, AstraZeneca Pty Ltd
Pleural Mesothelioma (PM)
 
 
ACTRN12609000141246: MATES: Maintenance Thalidomide in Mesothelioma Patients. A phase III trial of anti-angiogenic agent Thalidomide in patients with malignant pleural mesothelioma after first line chemotherapy.

Completed
3
100
 
University of Sydney, National Health and Medical Research Council
Unresectable malignant mesothelioma
 
 
2005-002736-10: Open, Randomised Phase II Study Assessing The Toxicity And Efficacy Of Platinum-Based Chemotherapy With Vitamin Supplementation In The Treatment Of Lung Cancer

Ongoing
3
84
Europe
Folic Acid, Gemcitabine, Vinblastine, Cisplatin, Vinorelbine, Docetaxel, Mitomycin-C, Etoposide, Vitamin B12, Carboplatin, Carboplatin
Royal Marsden Hospital
Non-small cell lung cancerSmall-cell lung cancerMalignant Mesothelioma (ICD classification code:C45.9)
 
 
CheckMate 743, NCT02899299 / 2016-001859-43: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Checkmark Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Sep 2022 - Sep 2022: Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Checkmark Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
Checkmark Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
More
Completed
3
605
Europe, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Mesothelioma
03/20
04/23
CONFIRM, NCT03063450 / 2016-003111-35: CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Active, not recruiting
3
332
Europe
Nivolumab, Opdivo, Placebo
University of Southampton, Bristol-Myers Squibb
Mesothelioma
02/23
02/23
INFINITE, NCT03710876 / 2017-003169-82: Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Active, not recruiting
3
53
Europe, Canada, US, RoW
rAd-IFN, Nadofaragene firadenovec, Celecoxib Oral Product, COX II Inhibitor, Gemcitabine, Chemotherapy
Trizell Ltd, University of Pennsylvania
Malignant Pleural Mesothelioma
11/23
11/24
AtezoMeso, NCT04996017 / 2020-003762-39: Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting
3
162
Europe
Atezolizumab 1200 mg in 20 ML Injection, Placebo
Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A.
Mesotheliomas Pleural
12/23
12/23
BEAT-meso, NCT03762018 / 2018-002180-25: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Active, not recruiting
3
401
Europe
Carboplatin, Carboplatin Accord, Pemetrexed, Alimta, Bevacizumab, Avastin, Atezolizumab, Tecentriq, RO5541267
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Pleural Mesothelioma Malignant Advanced
06/24
06/24
DREAM3R, NCT04181411: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Not yet recruiting
3
480
NA
Durvalumab, Imfinzi, MEDI4736, Cisplatin, Cisplatin injection, Pemetrexed, Alimta, Carboplatin, Carboplatin injection
University of Sydney, Australasian Lung Cancer Trials Group, PrECOG, LLC., AstraZeneca
Mesothelioma Malignant Advanced
06/24
06/24
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
04/25
12/25
NRG LU-006, NCT04158141: Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Terminated
3
16
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Decortication, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Pemetrexed, MTA, Multitargeted Antifolate, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Pencil Beam Scanning, Pleurectomy, Excision of Pleura, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
NRG Oncology, National Cancer Institute (NCI)
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB Pleural Malignant Mesothelioma AJCC v8, Stage II Pleural Malignant Mesothelioma AJCC v8, Stage IIIA Pleural Malignant Mesothelioma AJCC v8
11/23
11/23
eVOLVE-Meso, NCT06097728: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Volrustomig, MEDI5752, Pemetrexed, Alimta, Carboplatin, Paraplatin, Cisplatin, Platinol, Nivolumab, Opdivo, Ipilimumab, Yervoy
AstraZeneca
Unresectable Pleural Mesothelioma
03/27
03/28
2007-002574-63: Essai randomisé de phase 2-3 testant l’association Pemetrexed-Cisplatine avec ou sans bevacizumab à 15 mg/kg, dans le mésothéliome malin de la plèvre (MPM).

Ongoing
2/3
445
Europe
AVASTIN, AVASTIN, AVASTIN
CHU de Caen
pleural mesothelioma malignant
 
 
2008-003196-48: A phase II - III double-blind study of oral vinflunine plus best supportive care versus placebo plus best supportive care in patients with malignant pleural mesothelioma previously treated with systemic chemotherapy.

Ongoing
2/3
60
Europe
VINFLUNINE DITARTRATE, L00070,
PIERRE FABRE MEDICAMENT
Malignant pleural mesothelioma
 
 
DENIM, NCT03610360 / 2017-001774-41: DENdritic Cell Immunotherapy for Mesothelioma

Completed
2/3
176
Europe
MesoPher
Amphera BV, TMC Pharma
Mesothelioma
06/22
06/22
NCT02784171 / 2016-002286-60: Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Active, not recruiting
2/3
520
Europe, Canada
Cisplatin, Pemetrexed, Pembrolizumab
Canadian Cancer Trials Group, National Cancer Institute, Naples, Merck Sharp & Dohme LLC, Intergroupe Francophone de Cancerologie Thoracique
Mesothelioma
04/23
06/24
ACTRN12611000728932: A Randomised trial of predictive assay-directed chemotherapy in non-small cell lung cancer (NSCLC) and mesothelioma

Recruiting
2
85
 
Ballarat Cancer Research Centre, Ballarat Cancer Research Centre,
Non small cell lung cancer, Mesothelioma, Lung Cancer
 
 
NCT00060190: Pemetrexed Disodium and Gemcitabine in Treating Patients With Malignant Mesothelioma

Active, not recruiting
2
US
gemcitabine hydrochloride, pemetrexed disodium
University Hospitals Seidman Cancer Center, National Cancer Institute (NCI)
Malignant Mesothelioma
 
 
2012-000382-20: Personalized adjuvant systemic chemotherapy of patients affected by diffuse malignant peritoneal mesothelioma using in vitro chemosensitivity assay Trattamento chemioterapico personalizzato adiuvante del mesotelioma diffuso maligno del peritoneo sulla base dei test di chemiosensibilita' in vitro

Ongoing
2
40
Europe
Concentrate for solution for infusion, Powder for solution for infusion, Solution for infusion, CISPLATINO SANDOZ*EV 50MG 100M, ALIMTA*1FL POLV 500MG, DOXORUBICINA SAND.*10FL 10MG5M, GEMCITABINA SUN*INF FL 1G, NAVELBINE 10*IV 10MG 1ML
ISTITUTO NAZIONALE PER LA CURA TUMORI, Ministero della Salute - Ricerca Finalizzata
Patients affected by diffuse malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, without any factor precluding the performance of systemic adjuvant chemotherapy Pazienti affetti da mesotelioma diffuso maligno trattati con chirurgia radicale di citoriduzione associato a chemioipertermia intraperitoneale senza controindicazione a chemioterapia sistemica adiuvante, Patients affected by diffuse malignant peritoneal mesothelioma treated by radical surgery and eligible for systemic chemotherapy Pazienti affetti da mesotelioma diffuso maligno trattati con chirurgia radicale ed eleggibile a un trattamento chemioterapico, Diseases [C] - Cancer [C04]
 
 
2013-003830-34: Thoracic Mesothelioma: Surgery with or without subsequent lavage at high temperature with addition of chemotherapy Pleuramesotheliom: Operation mit oder ohne anschließender Spülung bei erhöhter Temperatur mit Zusatz von Chemotherapeutika

Ongoing
2
80
Europe
Cisplatin Teva, Solution for infusion, Cisplatin
Asklepios Fachkliniken München Gauting, Deutsches Zentrum für Lungenforschung
malignant pleuramesothelioma malignes Pleuramesotheliom, malignant pleural mesothelioma malignes Pleuramesotheliom, Diseases [C] - Cancer [C04]
 
 
2014-001992-30: Vinorelbine in Mesothelioma

Ongoing
2
200
Europe
Navelbine, Capsule, Navelbine
University of Leicester, Pierre Fabre Ltd
Histologically confirmed malignant pleural mesothelioma, Mesothelioma, Diseases [C] - Cancer [C04]
 
 
2005-002223-14: Fase II study of carboplatin and vinorelbine in malignant pleural mesothelioma

Ongoing
2
20
Europe
carboplatin, Vinorelbine, Navelbine, Carboplatin, navelbine, Navelbine, Carboplatin, navelbine, Navelbine
Rigshospitalet
Patients with malignant pleural mesothelioma who cannot be operated
 
 
2006-003742-42: A dose finding phase II study of Alimta in i.v. continuous infusion in patients with malignant pleural mesothelioma, non small cell lung cancer, pancreatic cancer and breast cancer

Ongoing
2
18
Europe
ALIMTA*1FL POLV 500MG, ALIMTA*1FL POLV 500MG
ISTITUTO ONCOLOGICO ROMAGNOLO
malignant pleural mesothelioma, non small cell lung cancer, pancreatic cancer and breast cancer
 
 
2007-005894-77: Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study)

Ongoing
2
110
Europe
NEXAVAR*112CPR RIV 200MG, CISPLATINO TEVA*EV 50MG 100ML, ALIMTA*1FL POLV 500MG, NEXAVAR*112CPR RIV 200MG, CISPLATINO TEVA*EV 50MG 100ML, ALIMTA*1FL POLV 500MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
malignant pleural mesothelioma (MPM)
 
 
2009-014293-17: Fase II studie met cetuximab in combinatie met cisplatinum of carboplatinum en pemetrexed als eerste lijnsbehandeling bij patiënten met borstvlieskanker (maligne pleuraal mesothelioom).

Ongoing
2
18
Europe
Cetuximab, Erbitux, Erbitux
University Hospital Ghent, Atrium MC Parkstad, , University Hospital Ghent
Patients with malignant pleural mesothelioma
 
 
2013-005621-24: Personalized treatment for patients with pleural effusions Gepersonaliseerde behandeling voor patiënten met pleuravocht

Ongoing
2
80
Europe
Gemcitabine, Carboplatin, Doxorubicin, Vinorelbine, Alimta, Oxaliplatin, Cisplatin, L01BC05, L01XA02, L01DB01, L01CA04, L01BA04, L01XA03, L01XA01, Gemcitabine, Carboplatin, Doxorubicine, Vinorelbine, Alimta, Oxaliplatin, Cisplatin, Gemcitabine, Carboplatin, Doxorubicine, Vinorelbine, Alimta, Oxaliplatin, Cisplatin
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis, Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Proven pleural effusion of malignant pleural mesothelioma or non small cell lung cancer Bewezen pleuravocht afkomstig van maligne pleura mesothelioom of niet kleincellig longkanker
 
 
DETERMINE, NCT01843374 / 2012-003524-21: Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Checkmark From DETERMINE trial in 2nd-line malignant mesothelioma
Jul 2017 - Jul 2017: From DETERMINE trial in 2nd-line malignant mesothelioma
Checkmark Completion of enrollment in P2 trial for malignant mesothelioma
Nov 2016 - Nov 2016: Completion of enrollment in P2 trial for malignant mesothelioma
Checkmark Of P2 DETERMINE trial in 2nd/3rd line mesothelioma due to safety/efficacy reason
More
Active, not recruiting
2
571
Europe, Canada, US, RoW
Tremelimumab, Placebo
MedImmune LLC
Unresectable Pleural or Peritoneal Malignant Mesothelioma
01/16
12/24
2012-005834-12: Switch maintenance treatment with gemcitabine for patients with malignant mesothelioma who do not progress after 1st line therapy with a pemetrexed-platinum combination. A randomised open label phase II study. NVALT 19 Onderhoudsbehandeling met gemcitabine bij patiënten met longvlieskanker bij wie de tumor niet groeit na de eerste lijn chemotherapie met een pemetrexed –platinum combinatie. Een gerandomiseerde fase II studie.

Ongoing
2
124
Europe
Gemcitabine, Gemcitabine
Stichting NVALT studies, Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis, KWF Kankerbestrijding, NVALT mesothelioma working party
Patients with histologically or cytologically proven malignant mesothelioma Patiënten met histologisch of cytologisch bewezen borstvlieskanker
 
 
2016-004727-23: TILT - a trial of a bacterial agent called OK432, administered directly into the chest via an indwelling catheter in people with cancer of the lung lining (mesothelioma).

Ongoing
2
45
Europe
Picibanil, Powder for solution for injection, Picibanil
North Bristol NHS Trust Research & Innovation, National Institute of Health Research
Malignant pleural mesothelioma, Cancer of the outside lining of the lung, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2017-003353-41: Mesothelioma Stratified Therapy (MiST) - Including the following treatment arms: MiST 1 rucaparibMiST 2 abemaciclibMiST 3 pembrolizumab in combination with bemcentinibMiST 4 atezolizumab in combination with bevacizumabMiST 5 dostarlimab in combination with niraparib

Not yet recruiting
2
120
Europe
rucaparib, abemaciclib, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), Pembrolizumab, bemcentinib, KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib, Dostarlimab, CO-338, LY2835219, R05541267/F03, RO4876646/F01, RO4876646/F02, MK-3475, BGB324, Tablet, Capsule, hard, Concentrate for solution for infusion, Solution for infusion, Capsule, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib
University of Leicester, The British Lung Foundation, Clovis Pharmaceuticals Inc., Eli Lilly & Company, Roche Pharma AG, Merck Sharp & Dohme Limited, BerGenBio ASA, GlaxoSmithKline Research & Development Limited
Malignant Mesothelioma (MM) - pleural and peritoneal, Mesothelioma is a universally lethal cancer caused by Asbestos. There has only been one licenced therapy since 2003. Accordingly there is a pressing need for effective therapy in the relapsed setting, Diseases [C] - Cancer [C04]
 
 
2019-002466-13: Nivolumab with chemotherapy in pleural mesothelioma after surgery

Not yet recruiting
2
92
Europe
Nivolumab, Concentrate for solution for infusion, Opdivo
Institut für Klinische Krebsforschung IKF GmbH, Bristol-Myers Squibb GmbH & Co. KGaA
Malignant Pleural Mesothelioma, Malignant Pleural Mesothelioma, Diseases [C] - Cancer [C04]
 
 
2019-001515-23: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma Etude de phase II multicentrique randomisée évaluant l’utilisation de la PIPAC en alternance avec la chimiothérapie systémique versus chimiothérapie systémique seule dans la 1ère ligne de traitement du Mésothéliome Péritonéal Malin

Not yet recruiting
2
66
Europe
Solution for injection, CISPLATIN, DOXORUBICIN, PEMETREXED
Institut Régional du Cancer de Montpellier, DGOS - PHRCK
Patient with Histologically-confirmed diagnosis of peritoneal malignant mesothelioma and non eligible for cytoreductive surgery Patients avec un diagnostic histologiquement confirmé d’un mésothéliome malin péritonéal non résécable., Patient with Histologically-confirmed diagnosis of peritoneal malignant mesothelioma and non eligible for cytoreductive surgery Patients avec un diagnostic histologiquement confirmé d’un mésothéliome malin péritonéal non résécable., Diseases [C] - Cancer [C04]
 
 
PrE0505, NCT02899195: Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Checkmark Data from PrE0505 trial in 1L unresectable mesothelioma
Nov 2021 - Nov 2021: Data from PrE0505 trial in 1L unresectable mesothelioma
Checkmark Data from PrE0505 trial in 1L unresectable mesothelioma at ASCO 2020
May 2020 - May 2020: Data from PrE0505 trial in 1L unresectable mesothelioma at ASCO 2020
Completed
2
55
US
Durvalumab, MEDI4736
PrECOG, LLC., AstraZeneca
Mesothelioma, Pleural Mesothelioma
02/20
06/23
2019-004388-37: A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural and Malignant Peritoneal MESOthelioma Patients: TALAMESO

Not yet recruiting
2
40
Europe
Capsule, TALZENNA
Hospices Civils de Lyon, PFIZER
This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma.The cohorts B1 will be patient populations with non-resected or incompletely resected disease and cohort B2, with completely resected disease., This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma., Not possible to specify
 
 
NCT01890980: Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

Active, not recruiting
2
60
US
WT-1-vaccine Montanide + GM-CSF, Montanide adjuvant + GM-CSF
M.D. Anderson Cancer Center, U.S. Army Medical Research and Materiel Command, Memorial Sloan Kettering Cancer Center, Sellas Life Sciences Group
Malignant Pleural Mesothelioma
04/20
04/21
NCT02879669 / 2015-005143-13: A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

Active, not recruiting
2
31
Europe
ONCOS-102, Pemetrexed/cisplatin (carboplatin), Cyclophosphamide
Targovax Oy, Theradex
To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
05/20
 
2019-003003-35: IMPALA IMPALA

Not yet recruiting
2
20
Europe
Nivolumab, BMS936558, Solution for injection, Nivolumab solution for injection
CHU de LILLE, Bristol-Myers Squibb
Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies in patients with malignant pleural mesothelioma Etude pilote de faisabilité d’un traitement innovant combinat la thérapie photodynamique intrapleurale et une immunothérapie adjuvante par Nivolumab chez des patients porteurs d’un mésothéliome pleural malin, Malignant Pleural Mesothelioma Mésothéliome Pleural Malin, Diseases [C] - Cancer [C04]
 
 
2020-000109-10: A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes Studio prospettico, multicentrico, di fase II, a braccio singolo, sulla combinazione Niraparib+Dostarlimab in pazienti con carcinoma polmonare non a piccole cellule avanzato e mesotelioma pleurico maligno, positivo per espressione di PD-L1 e mutazioni germinali o somatiche nei geni di riparo del danno al DNA

Ongoing
2
70
Europe
niraparib, DOSTARLIMAB, [MK-4827], [TSR-042], Capsule, hard, Solution for injection, ZEJULA, DOSTARLIMAB
DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO, GSK
patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes pazienti con carcinoma polmonare non a piccole cellule avanzato e mesotelioma pleurico maligno, positivo per espressione di PD-L1 e mutazioni germinali o somatiche nei geni di riparo del danno al DNA, patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes pazienti con carcinoma polmonare non a piccole cellule avanzato e mesotelioma pleurico maligno, positivo per espressione di PD-L1 e mutazioni germinali o somatiche nei geni di riparo del danno al DNA, Diseases [C] - Cancer [C04]
 
 
2019-002560-28: PEMbrolizumab Plus Lenvatinib in Malignant Pleural MEsotheLiomA Patients Pembrolizumab en lenvatinib bij maligne mesothelioom.

Not yet recruiting
2
58
Europe
Pembrolizumab, Lenvatinib, MK-3475, E7080, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK3475)
NKI-AVL, Merck & Co, inc.
unresectable malignant pleural mesothelioma, Asbestos cancer, Diseases [C] - Cancer [C04]
 
 
2019-002721-30: Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)

Ongoing
2
118
Europe
Yervoy, Opdivo, UV1, Leukine, BMS-936558, Infusion, Powder and solvent for solution for injection, Yervoy (ipilimumab), Opdivo (nivolumab), Leukine
Oslo University Hospital, BMS Pharmaceuticals Ltd, Ultimovacs
Malignant pleural mesothelioma (MPM), Malignant pleural mesothelioma (MPM), Diseases [C] - Cancer [C04]
 
 
TALAMESO, NCT04462809: Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma

Not yet recruiting
2
40
NA
Talazoparib
Hospices Civils de Lyon
Advanced Malignant Pleural or Peritoneal Mesothelioma
03/21
10/24
2020-005331-78: A study of SAR444245 combined with other anticancer therapies for the treatment of participants with lung cancer or mesothelioma Un estudio de SAR4443245 en combinación con otras terapias anticancerígenas para el tratamiento de participantes con cáncer de pulmón o mesotelioma

Ongoing
2
360
Europe
Tocilizumab, cisplatino, NA, pembrolizumab, nab-paclitaxel, pemetrexed, carboplatino, nab paclitaxel, SAR444245, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for dispersion for infusion, Keytruda, Pazenir, Abraxane
Sanofi-Aventis Recherche & Développement, SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT, Sanofi-Aventis Recherche & Développement
Pleural mesotheliomaNon-small cell lung cancer Mesotelioma Pleural Cáncer de Pulmón no microcítico, MesotheliomaLung cancer Mesotelioma Cáncer de pulmón, Diseases [C] - Cancer [C04]
 
 
NCT02611037: Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Active, not recruiting
2
34
US
Cisplatin, Platinol, Methotrexate, Trexall, Rheumatrex, Gemcitabine, Gemzar, Lung Cancer Symptom Scale for Mesothelioma Questionnaire, Quality of Life Assessment
H. Lee Moffitt Cancer Center and Research Institute
Malignant Pleural Mesothelioma, Mesothelioma
10/21
12/24
LungMate-010, NCT04713761: Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Not yet recruiting
2
15
NA
Toripalimab, carboplatin, pemetrexed
Shanghai Pulmonary Hospital, Shanghai, China
Malignant Pleural Mesothelioma
01/22
05/25
NCT03502746: Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Terminated
2
34
US
Nivolumab, Opdivo, Ramucirumab, Cyramza
Arkadiusz Z. Dudek, MD, HealthPartners Institute Regions Cancer Care Center, Eli Lilly and Company, Bristol-Myers Squibb
Mesothelioma, Malignant
05/22
11/23
NCT04290325: HMPL-453 in Advanced Malignant Mesothelioma

Recruiting
2
27
RoW
HMPL-453
Hutchison Medipharma Limited
Advanced Malignant Mesothelioma
11/22
03/23
MESOTIP, NCT03875144: Treatment of Malignant Peritoneal Mesothelioma

Recruiting
2
66
Europe
PIPAC, Cisplatin, Doxorubicin, Pemetrexed
Institut du Cancer de Montpellier - Val d'Aurelle
Peritoneal Mesothelioma, Peritoneal Carcinomatosis
09/26
09/28
NCT04013334: MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Active, not recruiting
2
12
US
MTG201, Ad-SGE-REIC/Dkk-3, Nivolumab Injection [Opdivo], Opdivo
Momotaro-Gene Inc., Baylor College of Medicine, Synteract, Inc.
Malignant Pleural Mesothelioma
12/22
01/23
NCT02755675 / 2015-005642-59: uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

Recruiting
2
120
Europe
68Ga-NOTA-AE105 PET/CT
Rigshospitalet, Denmark
Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma, Large Cell Neuroendocrine Carcinoma of the Lung
04/23
10/23
NCT05041062: A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Completed
2
2
US
Nivolumab, Opdivo, ONO-4538, BMS-936558, MDX1106, Ipilimumab, Yervoy
University of Chicago
Mesothelioma, Peritoneal Mesothelioma
04/23
04/23
NCT02436733: Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Active, not recruiting
2
64
Europe
pleurectomy/decortication, P/D, Pemetrexed/Cisplatin, CisPem
European Organisation for Research and Treatment of Cancer - EORTC
Malignant Pleural Mesothelioma
07/23
09/23
KEYNOTE-B71, NCT04914897 / 2020-005331-78: A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Active, not recruiting
2
106
Europe, Japan, US, RoW
THOR-707, Pembrolizumab, KEYTRUDA® or generic
Sanofi, Merck Sharp & Dohme LLC
Pleural Mesothelioma, Non-small Cell Lung Cancer
07/23
12/24
CanBenefitII, NCT05404022: Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years

Completed
2
11
Europe
Tailored nutrition and physical activity programme
University of Hull
Lung Neoplasm Malignant, Mesothelioma; Lung
09/23
09/23
MiST, NCT03654833: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
ChiCTR2200055419: A clinical study on the safety and efficacy of sintilimab combined with anlotinib hydrochloride and double-drug chemotherapy in the first-line treatment of patients with advanced malignant pleural mesothelioma

Suspended
2
29
 
Sintilimab combined with anlotinib hydrochloride and doublet chemotherapy
Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, Wu Jieping Medical Foundation Special Fund for Clinical Research
Lung Cancer
 
 
IMPROVE-I, NCT03656549: Dose Individualization of Pemetrexed -

Completed
2
6
Europe
Pemetrexed
Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Non Small Cell Lung Cancer, Mesothelioma
12/23
12/23
NEMO, NCT02863055 / 2016-000521-38: Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma

Active, not recruiting
2
37
Europe
Nintedanib, Placebo
European Organisation for Research and Treatment of Cancer - EORTC
Malignant Pleural Mesothelioma
03/24
03/24
ChiCTR2200055496: A single-center, phase II, exploratory clinical study on the efficacy and safety of bevacizumab injection combined with systemic chemotherapy in the treatment of malignant mesothelioma thoracic and ascites

Recruiting
2
30
 
Bevacizumab combined with systemic chemotherapy
Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital, None
Malignant pleural and peritoneal mesothelioma
 
 
PENINSULA, NCT06318286: Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

Not yet recruiting
2
25
Japan
Lenvatinib, E7080, Pemetrexed, Cisplatin/Carboplatin, Pembrolizumab, MK-3475
Hyogo Medical University, Merck Sharp & Dohme LLC
Malignant Pleural Mesothelioma
04/26
10/26
NIPU, NCT04300244: Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

Hourglass Jul 2022 - Dec 2022 : Top-line data from NIPU trial in combination with UV1 and Yervoy for malignant mesothelioma
Active, not recruiting
2
118
Europe, RoW
UV1 vaccine + leukine, ipilimumab, Yervoy, nivolumab, Opdivo
Åslaug Helland, Oslo University Hospital, Ultimovacs ASA, Bristol-Myers Squibb
Cancer, Cancer, Lung, Cancer of Lung, Mesothelioma, Mesothelioma; Lung, Mesothelioma; Pleura, Mesotheliomas Pleural
03/25
03/27
NCT02399371: Pembrolizumab in Treating Patients With Malignant Mesothelioma

Active, not recruiting
2
65
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Laboratory Biomarker Analysis, Pharmacogenomic Study
University of Chicago, National Cancer Institute (NCI)
Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Pleural Sarcomatoid Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Sarcomatoid Mesothelioma
03/26
03/26
NCT05337735: A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

Suspended
2
140
US
XmAb20717
M.D. Anderson Cancer Center
Microsatellite High Cancers, Peritoneal Mesothelioma, Extrapulmonary High Grade, Neuroendocrine Carcinomas, Cervical Carcinoma, Hodgkin's Lymphoma, Pleural Mesothelioma, Small Cell Lung Cancer
04/25
04/25
NCT03007030: Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Recruiting
2
55
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
04/25
04/25
NCT02153229: Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

Recruiting
2
102
US
Photodynamic Therapy, PDT, Radical Pleurectomy, RP, Chemotherapy, Photofrin 2.0 mg/kg
Abramson Cancer Center at Penn Medicine
Epitheliod Malignant Pleural Mesothelioma
05/24
12/24
NCT05429866: Immunological Variables Associated to ICI Toxicity in Cancer Patients

Recruiting
2
441
Europe
Checkpoint Blockade, Immune, Ipililumab, Nivolumab, Pembrozilumab, atezolizumab, avelumab, durvalumab, Cemiplimab
Jules Bordet Institute
Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Mesothelioma, Malignant, Bladder Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, MSI-H Colorectal Cancer
06/24
12/24
NCT05660616: Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma

Recruiting
2
40
RoW
Gemcitabine, Gemzar, supportive care
Ain Shams University
Malignant Pleural Mesothelioma
06/24
12/24
CHIMERA, NCT06155279: Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma ( Study)

Not yet recruiting
2
40
Europe
Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab, Keytruda
Istituto Oncologico Veneto IRCCS, MSD Italia S.r.l.
Pleural Mesothelioma
06/26
12/26
AK104-IIT 039, NCT06416930: Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Not yet recruiting
2
59
NA
Cadonilimab Combined with chemotherapy, AK104
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Akesobio
Pleural Mesothelioma
06/27
06/29
NCT06477419: A Study of Sacituzumab Govitecan in People With Mesothelioma

Recruiting
2
33
US
Sacituzumab govitecan-hziy
Memorial Sloan Kettering Cancer Center, Gilead Sciences
Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura
06/29
06/29
NCT03074513: Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Active, not recruiting
2
133
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar SCT501, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Stage III Merkel Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
09/25
09/25
UNITO-001, NCT04940637: - Study in HRR/PDL1 Positive MPM/NSCLC

Recruiting
2
70
Europe
niraparib and dostarlimab, no other intervention
University of Turin, Italy
Lung Cancer, Mesothelioma
06/24
06/25
NCT05188859: First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Not yet recruiting
2
29
RoW
Sintilimab+Anlotinib+Pemetrexed+Cisplatin, S+A+PC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
07/24
01/26
SAKK 17/18, NCT04480372: (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Completed
2
68
Europe
Gemcitabine, Atezolizumab
Swiss Group for Clinical Cancer Research
Malignant Pleural Mesothelioma, Non-small Cell Lung Cancer
03/23
04/24
NCT04515836: Olaparib in Patients With HRD Malignant Mesothelioma

Recruiting
2
56
US
Olaparib, Lynparza
University of Chicago, AstraZeneca
Mesothelioma, Homologous Recombination Deficiency
10/24
10/25
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NICITA, NCT04177953: Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Active, not recruiting
2
92
Europe
Carboplatin AUC 5, Cisplatin 75 mg/m2, Pemetrexed 500 mg/m2, Nivolumab Injection, Opdivo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb
Pleural Mesothelioma Malignant
12/24
01/25
PEMMELA, NCT04287829: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients

Active, not recruiting
2
58
Europe
Pembrolizumab, Lenvatinib
The Netherlands Cancer Institute, Merck Sharp & Dohme LLC
Mesotheliomas Pleural
12/24
03/25
A082101, NCT05647265: Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Recruiting
2
26
US
Nivolumab, 946414-94-4, BMS-936558, CMAB819, MDX-1106, NIVO, NIVOLUMAB, Nivolumab, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Ipilimumab, 477202-00-9, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, IPILIMUMAB, ipilimumab, Ipilimumab Biosimilar CS1002, MDX-010, MDX-010, MDX-CTLA4, Yervoy, Surgical Procedure, Computed Tomography, CAT, CAT Scan,, Magnetic Resonance Imaging, MRI, Positron Emission Tomography, Medical Imaging, PET, Pet Scan
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
12/24
12/24
ChiCTR2000040006: A Single-arm, Prospective, Phase II, Exploratory Clinical Study of Camrelizumab in Combination with Pemetrexed and Platinum in the First-line Treatment of Pleural Mesothelioma

Not yet recruiting
2
20
 
camrelizumab combined with pemetrexed and platinum
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital Chinese Academy of Medical Sciences, N/A
Pleural Mesothelioma
 
 
NERO, NCT05455424: Niraparib Efficacy in Patient With Unresectable Mesothelioma

Active, not recruiting
2
88
Europe
Niraparib Oral Product, Zejula, Active Symptom Control
University Hospital Southampton NHS Foundation Trust, University of Southampton, British Lung Foundation
Mesothelioma, Malignant
12/24
12/24
BIMES, NCT05005429 / 2020-004902-67: Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma

Recruiting
2
47
Europe
Bintrafusp alfa, M7824
Fundación GECP
Mesothelioma; Lung
03/25
04/25
REFIT-MSS, NCT05582031: Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Withdrawn
2
322
NA
Regorafenib in combination with Tislelizumab
Translational Research in Oncology, Bayer, Novartis
Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma, Small Cell Lung Carcinoma, Castrate Resistant Prostate Cancer, Neuroendocrine Carcinoma of Prostate, Gastroenteropancreatic Neuroendocrine Neoplasm
04/25
04/25
NCT03918252: Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Active, not recruiting
2
30
US
Nivolumab Injection, Optivo, Ipilimumab Injection, Yervoy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Mesothelioma
06/25
06/26
NCT00715611: Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

Active, not recruiting
2
65
US
Pleurectomy/Decortication, (P/D), pemetrexed and cisplatin or carboplatin, Intensity Modulated Radiation Therapy, IMRT
Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, Princess Margaret Hospital, Canada, Mayo Clinic, Brigham and Women's Hospital
Mesothelioma
07/25
07/25
NCT05930665: Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Recruiting
2
38
RoW
Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin, AK104
Sun Yat-sen University
Pleural Mesothelioma
07/25
07/26
NCT05380713: ......SMARTEST Trial......

Recruiting
2
30
Canada
Cyclophosphamide, Tremelimumab, Durvalumab
University Health Network, Toronto, OICR
Mesothelioma, Malignant
07/25
10/28
A092001, NCT05001880: Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Recruiting
2
66
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cytoreductive Surgery, Cytoreduction, Hyperthermic Intraperitoneal Chemotherapy, HIPEC, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Peritoneal Malignant Mesothelioma
08/25
08/25
ACROPOLI, NCT04802876: Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors

Recruiting
2
184
Europe
Spartalizumab, PDR001, Tislelizumab
SOLTI Breast Cancer Research Group, Novartis
MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma, Triple Negative Breast Cancer, Lung Adenocarcinoma, Cholangiocarcinoma, Cervical Carcinoma, Kidney Clear Cell Carcinoma, Stomach Adenocarcinoma, Esophageal Adenocarcinoma, Uterine Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Sarcoma, Lung Squamous Cell Carcinoma, Urothelial Carcinoma, Thyroid Carcinoma, Hepatocellular Carcinoma, Uveal Melanoma, HER2-positive Breast Cancer, Pancreatic Adenocarcinoma, Squamous Esophageal Carcinoma, Epithelial Ovarian Cancer, Uterine Carcinosarcoma, Small Cell Lung Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer, Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation, Colorectal Adenocarcinoma, Prostate Adenocarcinoma, Carcinoma of Unknown Primary, Other Histology
09/25
03/27
NCT05960773: Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Recruiting
2
15
US
Decitabine/cedazuridine
National Cancer Institute (NCI)
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
12/25
12/26
NCT05425576: OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Not yet recruiting
2
63
US
OT-101, Pembrolizumab
Oncotelic Inc.
Malignant Pleural Mesothelioma
12/28
12/29
IMPALA, NCT04400539: The IMmunotherapy Pleural 5-ALA PDT

Recruiting
2
20
Europe
intrapleural photodynamic therapy with videothoracoscopy, Nivolumab Injection, adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies
University Hospital, Lille, INSERM U1189 ONCOTHAI
Mesotheliomas Pleural, Malignant Pleural Mesothelioma
05/26
05/26
ChiCTR2200060395: A phase II study of PM8002 injection in combination with standard chemotherapy as first line therapy in unresectable malignant mesothelioma

Not yet recruiting
2
55
 
PM8002
Jilin Provice Cancer Hospital; Jilin Provice Cancer Hospital, Pumis Biotechnology (Zhuhai) Co., Ltd.
malignant mesothelioma
 
 
NCT05918107: A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

Recruiting
2
55
RoW
PM8002, Pemetrexed, Cisplatin, Carboplatin
Biotheus Inc.
MPM
06/26
06/26
KEYNOTE-158, NCT02628067 / 2015-002067-41: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/)

Dec 2023 - Dec 2023: Primary completion of P2 KEYNOTE-158 trial in advanced solid tumors
Checkmark Result from KEYNOTE-158 trial for 2L solid tumor
Sep 2022 - Sep 2022: Result from KEYNOTE-158 trial for 2L solid tumor
Checkmark ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
Mar 2021 - Mar 2021: ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
More
Recruiting
2
1609
Europe, Canada, US, RoW
pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
05/27
05/27
CheckMate 6DW, NCT05136677: A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

Recruiting
2
100
RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb
Mesothelioma, Malignant
10/26
10/26
MAGIC-AKI, NCT05730816: MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI

Recruiting
2
130
US
Magnesium sulfate, Normal Saline
Brigham and Women's Hospital, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Mesothelioma
04/27
01/28
 

Download Options